Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD
The Critical Interplay: CKD, HF, and Hyperkalemia
James Burton, DM, FRCP
Javed Butler, MD
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Javed Butler, MD, MPH, MBA
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Potassium Binders in Practice: Clinical Trial Evidence
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Implementing the SOC Induction Therapies in AAV
Silke R. Brix, MD, MRCP, SCPR
Bernhard Hellmich, MD
Managing Patients With AAV in the Rheumatology Clinic
Andreas Kronbichler, MD
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
Elevating Care for Patients With Severe Renal Disease in AAV
Unmasking IgAN: From Suspicion to Timely Diagnosis
Jörg Latus, MD
Chee Kay Cheung, MBCHB, MRCP, PHD
Finally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
Advances in IgAN Care From Kidney Week
Sydney Tang, MBBS, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.